MX2024008476A - Metodos de tratamiento de la fibrosis pulmonar idiopatica con deupirfenidona. - Google Patents

Metodos de tratamiento de la fibrosis pulmonar idiopatica con deupirfenidona.

Info

Publication number
MX2024008476A
MX2024008476A MX2024008476A MX2024008476A MX2024008476A MX 2024008476 A MX2024008476 A MX 2024008476A MX 2024008476 A MX2024008476 A MX 2024008476A MX 2024008476 A MX2024008476 A MX 2024008476A MX 2024008476 A MX2024008476 A MX 2024008476A
Authority
MX
Mexico
Prior art keywords
pulmonary fibrosis
idiopathic pulmonary
deupirfenidone
methods
treating idiopathic
Prior art date
Application number
MX2024008476A
Other languages
English (en)
Spanish (es)
Inventor
Paul Andrew Ford
Eric Elenko
Michael C Chen
Heather A Paden
Christopher C Korth
Julie S Krop
Camilla S Graham
Liza C Micioni
Simon John Hatch
Varun Garg
Original Assignee
Puretech Lyt 100 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretech Lyt 100 Inc filed Critical Puretech Lyt 100 Inc
Publication of MX2024008476A publication Critical patent/MX2024008476A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024008476A 2022-01-05 2023-01-05 Metodos de tratamiento de la fibrosis pulmonar idiopatica con deupirfenidona. MX2024008476A (es)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US202263296818P 2022-01-05 2022-01-05
US202263296843P 2022-01-05 2022-01-05
US202263296826P 2022-01-05 2022-01-05
US202263326132P 2022-03-31 2022-03-31
US202263326129P 2022-03-31 2022-03-31
US202263341281P 2022-05-12 2022-05-12
US202263341269P 2022-05-12 2022-05-12
US202263341279P 2022-05-12 2022-05-12
US202263341828P 2022-05-13 2022-05-13
US202263352107P 2022-06-14 2022-06-14
US202263356653P 2022-06-29 2022-06-29
US202263374362P 2022-09-01 2022-09-01
US202263403481P 2022-09-02 2022-09-02
US202263431530P 2022-12-09 2022-12-09
US202263432208P 2022-12-13 2022-12-13
PCT/US2023/060185 WO2023133476A1 (en) 2022-01-05 2023-01-05 Methods of treating idiopathic pulmonary fibrosis with deupirfenidone

Publications (1)

Publication Number Publication Date
MX2024008476A true MX2024008476A (es) 2024-07-12

Family

ID=87074293

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008476A MX2024008476A (es) 2022-01-05 2023-01-05 Metodos de tratamiento de la fibrosis pulmonar idiopatica con deupirfenidona.

Country Status (9)

Country Link
US (1) US20240358690A1 (enExample)
EP (1) EP4460305A4 (enExample)
JP (1) JP2025502023A (enExample)
KR (1) KR20240131352A (enExample)
AU (1) AU2023205787A1 (enExample)
CA (1) CA3239301A1 (enExample)
IL (1) IL314022A (enExample)
MX (1) MX2024008476A (enExample)
WO (1) WO2023133476A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023192646A1 (en) * 2022-03-31 2023-10-05 Puretech Lyt 100, Inc. Methods of treating fibrotic- and collagen-mediated diseases and disorders with deupirfenidone
WO2026133158A1 (en) * 2024-12-16 2026-06-25 Puretech Lyt 100, Inc. Deupirfenidone for use for treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases
WO2026133157A1 (en) * 2024-12-16 2026-06-25 Puretech Lyt 100, Inc. Deupirfenidone for use for treating idiopathic pulmonary fibrosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
AU2008265595B2 (en) * 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
IL319182A (en) * 2018-09-14 2025-04-01 Puretech Lyt 100 Inc Deuterium-enriched pirfenidone and methods of using it
US20250114341A1 (en) * 2018-09-14 2025-04-10 Puretech Lyt 100, Inc. Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
US20230129866A1 (en) * 2020-03-13 2023-04-27 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone

Also Published As

Publication number Publication date
JP2025502023A (ja) 2025-01-24
US20240358690A1 (en) 2024-10-31
AU2023205787A1 (en) 2024-06-13
IL314022A (en) 2024-08-01
WO2023133476A1 (en) 2023-07-13
EP4460305A1 (en) 2024-11-13
EP4460305A4 (en) 2025-12-31
CA3239301A1 (en) 2023-07-13
KR20240131352A (ko) 2024-08-30

Similar Documents

Publication Publication Date Title
JOP20200178A1 (ar) حلقات ضخمة كمعدلات لمنظم توصيل التليف الكيسي عبر الغشاء، وتركيبات صيدلانية منها، واستخدامها في علاج التليف الكيسي، وعملية لتصنيعها
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
PH12022552263A1 (en) Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
MX2025007797A (es) Derivado de tetrahidrotiofeno y uso de este en medicina
EP4647125A3 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
PL365224A1 (en) Nicotinic receptor agonists for the treatment of inflammatory diseases
MX2019005466A (es) Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia.
MX2022015146A (es) Tratamiento de la artritis reumatoide.
FI4426298T3 (fi) Uusia terapeuttisia yhdistelmiä, jotka käsittävät pirfenidonia ja pde4-estäjää, etenevien fibrosoivien interstitiaalisten keuhkosairauksien hoitamiseksi
MX2024008330A (es) Combinacion de obicetrapib e inhibidor de sglt2
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2025502023A5 (enExample)
MX2023005303A (es) Inhibidor de raf para el tratamiento del glioma de bajo grado.
MX2023009620A (es) Metodos terapeuticos.
MX2025005154A (es) Formulaciones orales compactables de ibutamoren.
MX2025012154A (es) Compuestos de pirimidina disustituidos para la inhibición de cetohexocinasa
PH12021551975A1 (en) Use of vibegron to treat overactive bladder
MX2025007590A (es) Pridopidina para el tratamiento de la enfermedad de huntington juvenil
CA2595363A1 (en) Methods and materials with trans-clomiphene for the treatment of male infertility
MX2024001266A (es) 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-d imorfolin-4-il-1,3,5-triazin-2-il)fenil]urea (gedatolisib) y sus combinaciones para usarse en el tratamiento de cancer.
MX2022012337A (es) Metodos para tratar esclerosis sistemica.
MX2023002422A (es) Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson.
PH12021553098A1 (en) Treatment for synucleinopathies
WO2024145288A3 (en) Methods of administering r-ketamine
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.